nach oben

Erschienen in:

01.09.2011

Familial breast cancer: is it time to move from a reactive to a proactive role?

verfasst von: H. Harris, I. Nippert, C. Julian-Reynier, J. Schmidtke, C. van Asperen, D. Gadzicki, A. Tibben, D. G. Evans

Erschienen in: Familial Cancer | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

In 2004 the NICE guidelines on familial breast cancer advised Health Care Professionals that they should not actively seek to identify women with a family history of breast cancer. We have carried out a review of the evidence base and a large scale questionnaire survey of health professionals in four European countries. There is overwhelming support amongst GPs and surgeons against the premise that that health care professionals should not be proactive in identifying patients at risk of familial breast cancer. This that suggest the time is right to overturn the NICE decision.

Grann VR, Jacobson JS, Thomason D et al (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 20(10):2520–2529PubMedCrossRef

van Roosmalen MS, Verhoef LC, Stalmeier PF et al (2002) Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. J Clin Oncol 20(8):2092–2100PubMedCrossRef

McIntosh A, Shaw C, Evans G, et al. (2004 updated 2006) Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer. National Collaborating Centre for Primary Care/University of Sheffield, London. NICE guideline CG041. www.nice.org.uk

Leach MO, Boggis CR, Dixon AK et al (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365(9473):1769–1778PubMedCrossRef

Kriege M, Brekelmans CT, Boetes C et al (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351(5):427–437PubMedCrossRef

Evans DGR, Baildam AD, Anderson E et al (2009) Risk reducing mastectomy: outcomes in 10 European Centres. J Med Genet 46(4):254–258PubMedCrossRef

Domchek SM, Friebel-Klingner TM, Neuhausen SL et al (2006) Mortality reduction after risk-reducing bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Lancet Oncol 7(3):223–229PubMedCrossRef

Domchek SM, Friebel TM, Singer CF et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967–975PubMedCrossRef

FH01 Management Committee, Steering Committee, Collaborators (2010) Tumour attributes and implications for future mortality in the FH01 study of mammographic surveillance in women aged 40–49 with a family history of breast cancer. Lancet Oncol 11(12):1127–1134CrossRef

Titel: Familial breast cancer: is it time to move from a reactive to a proactive role?
verfasst von: H. Harris
I. Nippert
C. Julian-Reynier
J. Schmidtke
C. van Asperen
D. Gadzicki
A. Tibben
D. G. Evans
Publikationsdatum: 01.09.2011
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 3/2011
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-011-9434-1

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Familial breast cancer: is it time to move from a reactive to a proactive role?

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Cancer worry among Norwegian male BRCA1/2 mutation carriers

Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families

Low penetrance hereditary retinoblastoma in a family: what should we consider in the genetic counselling process and follow up?

Familial colorectal cancer: eleven years of data from a registry program in Switzerland

Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer

Gastrointestinal polyps and cancer in Peutz-Jeghers syndrome: clinical aspects

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie